💨 Abstract

Sarepta Therapeutics' shares rose over 16% after the FDA allowed resumption of its gene therapy, Elevidys, for young Duchenne's muscular dystrophy patients who can walk. The move follows a pause due to deaths of older patients. An 8-year-old's death was deemed unrelated to the therapy. The FDA is still evaluating the drug's use in older patients and requires new safety data for further approval. The decision boosts the drug's near-term sales outlook.

Courtesy: WTOP Staff